Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Search
Generalized pustular psoriasis at EADV 2021
Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Lung Diseases
Lung Diseases
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Brigimadlin (BI 907828)
Brigimadlin BI 907828
Brigimadlin
MDM2-p53 antagonist
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Transforming pig farming through AI
With our livestock farming technology based on sound analytics, we are improving pig farm practices, producing healthier pigs and a better farm economy.
PRRS vaccine discovery for swine
PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Immunomodulator
Immunomodulator
STING agonist (2nd generation)
Second generation STING agonist
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
Ezabenlimab
Ezabenlimab, PD-1 antibody
PD-1 antibody
PD-1 antibody
TREM-1 Antibody
TREM-1 Antibody
Phospholipid modulator
Phospholipid modulator
Vascular modulator
Vascular modulator
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
Survodutide (BI 456906)
Survodutide (BI 456906)
Glutamate receptor modulator
Glutamate receptor modulator
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.